Mynewsdesk LinkedIn
Press & News

The next generation biopharmaceuticals

Press releases 2013

Older press releases

2013-11-05

Sobi announces phase I Complement Inhibitor program

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial today at the company’s Capital Markets Event in Stockholm.[read more]

2013-10-01

EU Funded Effort to Develop New Stroke Therapies

Solna, Sweden, October 1, 2013. The COUNTERSTROKE consortium led by researchers at Karolinska Institutet today initiates a six million Euro EU funded collaboration to develop novel therapeutics to treat stroke.[read more]

2013-09-17

New molecular imaging agents being developed for fluorescence-guided brain cancer surgery

Solna, Sweden, September 17, 2013. Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery.[read more]

« Older press releases

Affibodys latest Press releases

2020-06-15

Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)

Investor information